Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade A 150.51 1.16% 1.73
ARGX closed up 1.16 percent on Thursday, July 18, 2019, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARGX trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
NR7 Range Contraction 0.00%
New 52 Week High Strength 0.00%
Multiple of Ten Bullish Other 0.00%
BB Squeeze Ended Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%

Older signals for ARGX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Rheumatoid Arthritis Acute Myeloid Leukemia Myelodysplastic Syndrome Dyslipidemia Hematological Cancers Treatment Of Autoimmune Diseases Myasthenia Gravis Janus Kinase Inhibitor Treatment Of Hematological Cancers Tolerx
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 150.92
52 Week Low 63.81
Average Volume 168,844
200-Day Moving Average 113.0856
50-Day Moving Average 132.0076
20-Day Moving Average 141.155
10-Day Moving Average 142.242
Average True Range 3.5285
ADX 20.13
+DI 40.2805
-DI 19.2456
Chandelier Exit (Long, 3 ATRs ) 140.3345
Chandelier Exit (Short, 3 ATRs ) 138.2755
Upper Bollinger Band 148.8658
Lower Bollinger Band 133.4442
Percent B (%b) 1.11
BandWidth 10.925295
MACD Line 4.2753
MACD Signal Line 3.6302
MACD Histogram 0.6451
Fundamentals Value
Market Cap 4.04 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -118.51
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 154.04
Resistance 3 (R3) 153.78 152.35 153.45
Resistance 2 (R2) 152.35 151.45 152.48 153.25
Resistance 1 (R1) 151.43 150.90 151.89 151.69 153.06
Pivot Point 150.00 150.00 150.23 150.13 150.00
Support 1 (S1) 149.08 149.10 149.54 149.34 147.96
Support 2 (S2) 147.65 148.55 147.78 147.77
Support 3 (S3) 146.73 147.65 147.57
Support 4 (S4) 146.99